Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2004
DOI:
https://doi.org/10.33321/cdi.2006.30.7Keywords:
antimicrobial resistance, disease surveillance, gonococcal, Neisseria gonorrhoeae, World Health Organization Western Pacific RegionAbstract
The World Health Organization Western Pacific Region Gonococcal Antimicrobial Surveillance Programme (WHO WPR GASP) examined approximately 10,000 isolates of Neisseria gonorrhoeae from 15 countries for resistance to antibiotics in 2004. Treatment options for gonorrhoea in the Region are limited by persisting high rates of resistance to penicillins and quinolones. There were infrequent instances of spectinomycin resistance and the presence of gonococci with decreased susceptibility to third generation cephalosporins was again noted in several centres. Commun Dis Intell 2006;30:129–132.
Downloads
References
World Health Organization Western Pacific Region Gonococcal Surveillance Programme. Surveillance of antibiotic susceptibility of Neisseria gonorrhoeae in the WHO Western Pacific Region 1992–4. Genitourin Med 1997;73:355–361.
WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2003. Commun Dis Intell 2005;29:62–64.
Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Eng J Med 1987;317:272–278.
Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, Ito S, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harbouring mosaic-like structure of penicillin-binding protein 2 in Japan. Antimicrob Agent Chemother 2005;49:137–143.
Tapsall JW. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/CSR/DRS/2001.3. World Health Organization, Geneva, Switzerland, 2001. Available from: http://www.who.int/entity/drugresistance/Antimicrobial_resistance_in_Neisseria_gonorrhoeae.pdf
Management of sexually transmitted diseases. World Health Organization 1997; Document WHO/GPA/TEM94.1 Rev.1 p 37.
Shultz TR, Tapsall JW, White PA. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob Agent Chemother 2001;45:734–738.
Simonsen GS, Tapsall JW, Allegranzi B, Talbot EA, Lazzari S. The ARCS Approach – A Public Health Tool for antimicrobial resistance containment and surveillance. Bull World Health Org 2004;82:928–934
Tanaka M, Nakayama H, Huruya K, Konomi I, Irie S, Kanayama A, et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone that shows a multidrug-resistant phenotype. Int J Antimicrob Agent 2006;27:20–26.
Wang SA, Lee MAC, O'Connor N, Iverson CJ, Ohye RG, Whiticar PM, et al. Multi-Resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime—Hawaii, 2001. Clin Infect Dis 2003;37:849–852.
Hoffman SH, Lambertson L, Berthelsen L, Cowan. Neisseria gonorrhoeae with increasing cetriaxon MIC in Denmark in 2004: serotyping, bi-locus sequence typing and sexual preference. In: Proceedings of the 16 th Biennial Meeting of the International Society for STD Research, Amsterdam, 2005: Abstract WP-035.
Tapsall JW. What management is there for gonorrhea in the post-quinolone era? Sex Transm Dis 2006;33:8–10.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2006 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
